HOUSTON, May 5, 2021 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary aesthetic platform technology,
today announced the launch of its highly anticipated Rapid Acoustic
Pulse™ (RAP) device — RESONIC™. The dual-platform RESONIC™ device
utilizes a first-of-its-kind technology and offers a
paradigm-shifting approach to two in-demand procedures: tattoo
removal and cellulite treatment. Harnessing the power of sound,
RESONIC helps achieve 75% greater fading of tattoos in as few as 3
sessions and improves the appearance of cellulite non-invasively
with high patient satisfaction after just 1 treatment
session.
"This is an exciting day for Soliton and the RESONIC brand,"
shared Brad Hauser, President &
CEO of Soliton. "It's been a long time in the making and we're
excited to finally bring this innovative and efficacious solution
to procedures that have had historically low patient satisfaction
or required numerous treatment sessions to achieve expected
results. Launching RESONIC with two unique indications has been a
strategic goal of ours since receiving our first FDA clearance in
2019. This approach enables our HCP partners to drive multiple
revenue streams among two different patient profiles with one
device, positioning our partners for accelerated practice growth,
and poising RESONIC to become a leading aesthetics brand," added
Hauser.
Leveraging its proprietary technology, the RESONIC device is
designed to safely deliver rapid, high-pressure acoustic shockwaves
at a rate of up to 100 pulses per second, resulting in the physical
change of targeted cellular structures without creating cavitation
or heating that could result in surrounding tissue damage. The
Rapid Acoustic Pulse technology creates a new standard in tattoo
removal when used as an accessory to a Q-Switched laser, to allow
for multiple laser passes and up to 44% fading in a single session
with tattoo removal in as few as 3 sessions. This innovative
technology also safely and non-invasively physically changes
fibrous septa bands beneath the skin that cause cellulite to
deliver efficacious results in just one, 45–60-minute treatment
with minimal discomfort and without downtime.
"RESONIC revolutionizes the industry's approach to two
notoriously challenging patient needs. The technology's ability to
physically change targeted cellular structures without breaking the
skin is game changing," shared Dr. Elizabeth Tanzi, Board Certified Dermatologist
and member of Soliton's Scientific Advisory Board. "Clinical trial
results for both RESONIC procedures showed significant results with
accelerated treatment timelines, which I believe will result in
higher patient satisfaction and will minimize common barriers to
entry that exist for tattoo removal and cellulite reduction."
RESONIC is cleared by the U.S. Food and Drug Administration
(FDA) as an accessory to the 1064 nm Q-Switched laser for black ink
tattoo removal in Fitzpatrick Skin Type I-III patients and
short-term improvement in the appearance of cellulite.
RESONIC for Tattoo and RESONIC for Cellulite will be available
through a select network of physicians and medically supervised
spas beginning in June 2021. Visit
http://www.RESONIC.com/ for more information and to find a
physician near you.
------------------------
About RESONIC™
The RESONIC™ Rapid Acoustic Pulse™ (RAP) technology is the first
and only technology of its kind specially engineered to safely
generate high-frequency acoustic waves up to 100 times per second
to change targeted structures in your skin down to the cellular
level. The FDA-cleared RESONIC device is used as an accessory to
the 1064 nm Q-Switched laser for black ink tattoo removal in
Fitzpatrick Skin Type I-III patients and to temporarily improve the
appearance of cellulite. RESONIC is powered by Soliton, Inc, a
medical device company based in Houston,
Texas with a novel and proprietary platform developed to
revolutionize the aesthetics industry.
To learn more and view important safety information, visit
http://www.resonic.com/.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer
Center. The Company's first FDA cleared commercial product,
RESONIC™, will use rapid pulses of acoustic shockwaves as an
accessory to lasers for the removal of unwanted tattoos and the
treatment of cellulite. The Company is based in Houston, Texas, and is actively engaged in
bringing RESONIC to the market. The Company believes this "Soliton"
method has the potential to lower tattoo removal costs for
patients, while increasing profitability to practitioners, compared
to current laser removal methods. The Company also believes the
technology will provide the first non-invasive acoustic technology
to target the underlying causes of dimples and ridges in cellulite.
Soliton is investigating potential additional capabilities of the
RAP technology. The device is currently cleared in the United States only for use in tattoo
removal and cellulite.
For more information about the Company, please visit
http://www.soliton.com/.
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which statements involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, our ability to successfully
commercialize our RESONIC device. These statements relate to
future events, future expectations, plans and prospects. Although
Soliton believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
actual results or outcomes may prove to be materially different
from the expectations expressed or implied by such forward-looking
statements. Soliton has attempted to identify forward-looking
statements by terminology including ''believes,'' ''estimates,''
''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,''
''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' "would,"
''should,'' ''approximately'' or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, including those discussed in our filings with the
Securities and Exchange Commission ("SEC"), including under the
heading " Risk Factors" in our most recently filed Form 10-K filed
with the SEC and as updated in our Form 10-Q filings and in our
other filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/introducing-resonic-301283971.html
SOURCE Soliton, Inc.